1. Effect of liraglutide in different abdominal fat layers measured by ultrasound. The importance of perirenal fat reduction
- Author
-
Guillem Cuatrecasas, Marta Calbo, Olga Rossell, Laia Dachs, Gerardo Aguilar-Soler, Maria-José Coves, Ioana Patrascioiu, Camila Eugenia Benito, Sonia March, Mariona Balfegó, Gabriel Cuatrecasas, Silvana Di Gregorio, Inaki Marina, Pilar Garcia-Lorda, Elena Munoz-Marron, and Francisco De Cabo
- Subjects
Nutrition. Foods and food supply ,TX341-641 ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Introduction: Ultrasonography in patients with Obesity allows us to measure different layers of abdominal fat (Superficial subcutaneous, Deep subcutaneous, Preperitoneal, Omental and Perirenal), not assessable by DEXA or CT scan. Omental and Perirenal fat depots are considered predictors of metabolic complications. Liraglutide is particularly effective in reducing weight in patients with insulin-resistance, but its direct impact on each abdominal fat layer is unknown. Methods: We measured, at the L4 level, all 5 abdominal fat depots in 860 patients with obesity (72.8% women. Mean age 56.6±1.5 years. BMI 34.4±4.7 kg/m2. Body fat 47±2%. Abdominal circumference 105.8±3 cm), before and after 6 months of Liraglutide treatment. Laboratory tests for glucose, insulin and lipid profile were routinely done. T-student was used to compare intra-individual differences. Results: Weight loss was 7.5±2.8 Kg (7.96% from baseline), with no differences by sex/age/BMI. Greater loss was observed in patients with higher dosages and NAFLD. All US-measured fat layers showed a significant reduction (p
- Published
- 2024
- Full Text
- View/download PDF